Ajay Sheshadri, MD, discusses the advantages of attending CHEST 2023 in person and how these benefits can inspire positive change even after the conference ends.
Seeing colleagues in person at the CHEST Annual Meeting 2023 is a valued opportunity after the COVID-19 pandemic and provides advantages for all areas of medicine even after the conference ends, explains Ajay Sheshadri, MD, associate professor of pulmonary medicine at the University of Texas MD Anderson Cancer Center.
Transcript
Why is it beneficial for chest medicine professionals to meet in person at CHEST 2023?
I think we probably took for granted how great it is to see our colleagues in person before the pandemic. During the pandemic, most of our conferences were virtual, and the engagement with the virtual conference is a lot more difficult. You're not there in person seeing the speakers, you're not able to interact with the speakers, other than through a chat box or perhaps a very closely moderated Q&A, and it doesn't quite feel like you're in a research retreat environment.
So, being around people of like-minded interests really just stimulates your own desire to advance the field forward, and I think gives you a lot of energy to be able to motivate yourself when you come back from the conference. Usually, after the conference, there's a little bit of a buzz as you synthesize all the things that you saw and discussed at the conference. To me, that's been incredibly beneficial. Usually after the meetings, there's a flurry of activity and new collaborations and new ideas, and I think you only really get that when you’re there in person and really in the moment.
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Community Oncology Reacts to Trump's Drug Pricing Executive Order
May 2nd 2025An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Read More